September 2025 in “Journal of the Pakistan Medical Association” Tofacitinib effectively and safely promotes hair regrowth in alopecia patients.
July 2025 in “Journal of Cosmetic Dermatology” Alternative treatments are needed when Tofacitinib alone fails for alopecia areata.
August 2020 in “Ugeskrift for Læger” A man with severe hair loss regrew all his hair using tofacitinib and stayed healthy for a year.
August 2023 in “Journal of Cosmetic Dermatology” Higher concentration of botulinum toxin A is safe and effective for treating hair loss in men and women.
Oral tofacitinib effectively treats alopecia areata long-term with manageable side effects.
May 2023 in “Research Square (Research Square)” Botulinum toxin type A helps treat hair loss by stopping cell death in hair follicles through a process involving certain non-coding RNAs and a protein called Bax.
January 2024 in “Aesthetic Plastic Surgery” Botox can help prevent hair loss by blocking cell death in scalp cells.
Baricitinib effectively promotes regrowth of eyebrows and eyelashes in alopecia areata patients.
March 2025 in “Indian Journal of Dermatology Venereology and Leprology” Tofacitinib is effective for treating alopecia totalis and universalis, with some patients experiencing significant hair regrowth.
June 2023 in “British Journal of Dermatology” Baricitinib was effective and safe for severe hair loss treatment over 6 months.
3 citations
,
November 2020 in “Dermatologic Therapy” Start with 2.5 mg/mL triamcinolone acetonide for scalp alopecia areata and increase if needed.
January 2023 in “National Journal of Physiology, Pharmacy and Pharmacology” Tofacitinib effectively reduced hair loss in alopecia areata patients without adverse effects.
19 citations
,
October 2013 in “Headache: The Journal of Head and Face Pain” The document concludes that inhalation of oxygen and sumatriptan injections are primary for cluster headaches, indomethacin for paroxysmal hemicrania, and lidocaine and lamotrigine for SUNCT, but SUNCT often resists treatment.
Baricitinib therapy helped many patients with severe alopecia regrow hair after 52 weeks.
7 citations
,
March 2021 in “Journal of the American Academy of Dermatology” Tofacitinib can regrow hair in alopecia areata patients, but some may experience flares during treatment.
May 2023 in “International Journal of Trichology” Tofacitinib effectively treated severe hair loss in a patient who didn't respond to other treatments.
May 2025 in “International Journal of Trichology” Topical tofacitinib may help regrow hair in children with alopecia totalis.
69 citations
,
August 2006 in “Behavior Therapy” Group behavior therapy reduces hair-pulling symptoms more than supportive therapy but has limited long-term effectiveness.
November 2024 in “Journal of Cosmetic Dermatology” Baricitinib is effective for severe alopecia areata but has some side effects.
May 2023 in “International Journal of Trichology” Tofacitinib may be an effective and safe treatment for hair loss in teenagers with alopecia areata.
October 2024 in “International Journal of Research in Dermatology” Tofacitinib is a promising and safe treatment for moderate to severe alopecia areata.
November 2024 in “Journal of the European Academy of Dermatology and Venereology” Long-term baricitinib treatment can lead to significant scalp hair regrowth in patients initially showing only eyebrow or eyelash regrowth.
September 2024 in “Journal of the American Academy of Dermatology” Botulinum toxin is not effective for treating male hair loss.
August 2022 in “Dermatology Online Journal” Oral and topical tofacitinib can effectively treat severe hair loss with minimal side effects.
49 citations
,
March 2017 in “Journal of the American Academy of Dermatology” Tofacitinib caused significant hair regrowth in adolescents with alopecia universalis who didn't respond to other treatments.
November 2023 in “Dermatology and Therapy” Baricitinib treatment helps regrow eyebrow, eyelash, and scalp hair in severe alopecia areata, improving patients' emotional well-being and quality of life.
16 citations
,
January 2021 in “Journal of the American Academy of Dermatology” Asynchronous telemedicine for acne treatment is effective and improves access and productivity.
44 citations
,
October 2017 in “Journal of the American Academy of Dermatology” Tofacitinib is effective and safe for treating severe hair loss in Korean patients.
September 2025 in “The health sciences AUS.” Intralesional triamcinolone acetonide effectively treats acne keloidalis nuchae with minimal side effects.
November 2025 in “Archives of Dermatological Research” Using a higher concentration of triamcinolone acetonide leads to faster hair regrowth in scalp patchy alopecia areata.